Safety of rapid subcutaneous gammaglobulin infusions in patients with primary antibody deficiency.
Gardulf
A
A
Dept. of Clinical Immunology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden.
Björvell
H
H
Gustafson
R
R
Hammarström
L
L
Smith
C I
CI
D000293:Adolescent; D000328:Adult; D000361:Agammaglobulinemia / Q000628:therapy; D000368:Aged; D005260:Female; D006801:Humans; D017098:IgA Deficiency / Q000628:therapy; D017099:IgG Deficiency / Q000628:therapy; D007153:Immunologic Deficiency Syndromes / Q000628:therapy*; D007263:Infusions, Parenteral; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D012449:Safety; D012646:Self Administration; D005719:gamma-Globulins / Q000008:administration & dosage* / Q000009:adverse effects*
D005719:gamma-Globulins